Literature DB >> 16115518

Clinical trials in diastolic heart failure.

Barry M Massie1, Mary Rose Fabi.   

Abstract

Forty percent to 50% of patients with chronic heart failure have normal or relatively normal left ventricular ejections fractions. These are much more frequently women and tend to be older than those with reduced ejection fractions. In most, left ventricular diastolic dysfunction plays a major role in the genesis of heart failure. Until recently, these patients have been systematically excluded from heart failure trials, so that there are no proven treatments for this group. This article reviews the recent and ongoing trials in patients with diastolic heart failure, which hopefully will lead to improved treatment and outcomes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16115518     DOI: 10.1016/j.pcad.2005.02.005

Source DB:  PubMed          Journal:  Prog Cardiovasc Dis        ISSN: 0033-0620            Impact factor:   8.194


  5 in total

Review 1.  Implantable hemodynamic monitoring devices in heart failure.

Authors:  Salpy V Pamboukian; Melissa C Smallfield; Robert C Bourge
Journal:  Curr Cardiol Rep       Date:  2006-05       Impact factor: 2.931

Review 2.  Office management of patients with diastolic heart failure.

Authors:  Katina Tzanetos; Derek Leong; Robert C Wu
Journal:  CMAJ       Date:  2009-03-03       Impact factor: 8.262

3.  Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: diagnosis and management.

Authors:  J Malcolm O Arnold; Peter Liu; Catherine Demers; Paul Dorian; Nadia Giannetti; Haissam Haddad; George A Heckman; Jonathan G Howlett; Andrew Ignaszewski; David E Johnstone; Philip Jong; Robert S McKelvie; Gordon W Moe; John D Parker; Vivek Rao; Heather J Ross; Errol J Sequeira; Anna M Svendsen; Koon Teo; Ross T Tsuyuki; Michel White
Journal:  Can J Cardiol       Date:  2006-01       Impact factor: 5.223

Review 4.  Cardiovascular alteration and treatment of hypertension: do men and women differ?

Authors:  Shawna M McBride; Francis W Flynn; Jun Ren
Journal:  Endocrine       Date:  2005-11       Impact factor: 3.633

Review 5.  Neuregulins: protective and reparative growth factors in multiple forms of cardiovascular disease.

Authors:  Andrew Geissler; Sergey Ryzhov; Douglas B Sawyer
Journal:  Clin Sci (Lond)       Date:  2020-10-16       Impact factor: 6.876

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.